Mapping large numbers of results may take a few moments.
Search Results
Showing 51 - 100 of 252 results found.
| Company | Activity | Company Description | Location | |
|---|---|---|---|---|
 |
Company BridgeBio Gene Therapy | Activity: Research and Development | Company Description BridgeBio Gene Therapy is developing a gene therapy for the treatment of a monogenic disease that presents in childhood. | Location Raleigh |
| |
Company Brii Biosciences Inc. | Activity: Research and Development | Company Description Brii Biosciences develops therapies focused on infectious diseases and central nervous system diseases where patients experience high levels of unmet medical needs, limited choice and significant social stigmas. | Location Durham |
| |
Company Bryn Pharma LLC | Activity: Research and Development | Company Description Bryn Pharma is developing a nasal solution for the administration of emergency epinephrine for the treatment of anaphylaxis. | Location Raleigh |
| |
Company Caeregen Therapeutics LLC | Activity: Research and Development | Company Description Caeregen Therapeutics develops therapies which repair, restore, and protect damaged and diseased tissues by reactivating the pathways and signaling which accompany normal cellular and tissue development. Caeregen is developing Noregen, a recombinant protein mimetic of human norrin-derived growth factor for the potential treatment of retinal-related vision loss. | Location Chapel Hill |
| |
Company Cancer Advances Inc. | Activity: Research and Development | Company Description Cancer Advances, a subsidiary of Cato Bioventures, develops immunomodulator therapeutics to treat gastrointestinal cancers. | Location Durham |
| |
Company CardioPharma Inc. | Activity: Research and Development | Company Description CardioPharma develops combinatorial products to treat cardiovascular disease. | Location Wilmington |
| |
Company Cellective BioTherapy Inc. | Activity: Research and Development | Company Description Cellective BioTherapy is developing cellular and monoclonal antibody-based platforms for treating cancers, autoimmunity and immunodeficiency through the manipulation of B cells and their functional subsets. | Location Chapel Hill |
| |
Company Cessation Therapeutics | Activity: Sales and Operations | Company Description Cessation Therapeutics is developing novel antibody therapies to prevent and reverse overdose related to fentanyl and related synthetic opioids. The Chapel Hill site is Cessation's corporate office. | Location Chapel Hill |
| |
Company Chiesi USA Inc. | Activity: Research and Development | Company Description Chiesi USA, the U.S. affiliate of Chiesi Farmaceutici S.p.A, develops and commercializes products in the therapeutic areas of rare disease, respiratory, cardiovascular, neonatology and cystic fibrosis. | Location Cary |
| |
Company Chimerix Inc. | Activity: Research and Development | Company Description Chimerix discovers, develops and commercializes broad spectrum antivirals for the prevention and treatment of life-threatening viral infections. | Location Durham |
| |
Company Citranvi Biosciences LLC | Activity: Research and Development | Company Description Citranvi develops vaccine technology platforms and products, using comprehensive structure-based vaccine design, broadly applicable to a variety of viral pathogens such as Cytomegalovirus, Epstein-Barr Virus and Coronaviruses. | Location Chapel Hill |
| |
Company Claradele Pharmaceuticals Inc. | Activity: Research and Development | Company Description Claradele Pharmaceuticals is developing an immunotherapy product to treat melanoma. | Location Winterville |
| |
Company Clarus Biologics Inc. | Activity: Research and Development | Company Description Clarus Biologics is developing innovative vaccine and immunotherapeutic products using a novel and proprietary self-amplifying mRNA delivery and viral particle technology platform. Its first innovation is a vaccine VLP that enhances the effectiveness, efficiency and availability of vaccines. | Location Chapel Hill |
| |
Company Cognosci Inc. | Activity: Research and Development | Company Description Cognosci develops neurorestorative therapies for Alzheimer's disease, multiple sclerosis, traumatic brain injury, nerve crush and other disease and trauma indications. | Location Durham |
| |
Company Countervail Corp. | Activity: Research and Development | Company Description Countervail is developing proprietary drug and diagnostic technologies to detect exposure to and prevent adverse effects from organophosphate pesticides. | Location Mint Hill |
| |
Company Couragen Biopharmaceutics LLC | Activity: Research and Development | Company Description Couragen Biopharmaceutics develops gene and protein therapy products for preclinical and clinical use for the treatment of genetic and chronic diseases. Couragen also provides custom adeno-associated virus vectors as a tool for laboratory research. | Location Chapel Hill |
| |
Company Creyon Bio | Activity: Research and Development | Company Description Creyon Bio is a drug development company engineering RNA-based medicines and their components. | Location Research Triangle Park |
| |
Company Dechra Pharmaceuticals | Activity: Research and Development | Company Description Dechra Pharmaceuticals develops veterinary pharmaceuticals with a focus on major companion animal categories. | Location Greensboro |
| |
Company DelAQUA Pharmaceuticals Inc. | Activity: Research and Development | Company Description DelAQUA Pharmaceuticals is developing technology to enhance the solubility and stability of drugs and drug candidates and to improve their efficacy and safety. | Location Chapel Hill |
| |
Company Denizen Biologics LLC | Activity: Research and Development | Company Description Denizen Biologics develops gene therapy vectors to enhance the capability of genetic medicine and improve the outcomes for patients. | Location Cary |
| |
Company Dermavant Sciences | Activity: Research and Development | Company Description Dermavant, a part of the Roivant family of companies, develops therapies for the treatment of skin diseases. | Location Morrisville |
| |
Company Dignify Therapeutics LLC | Activity: Research and Development | Company Description Dignify Therapeutics develops novel bowel and bladder therapies for people with neurological disorders and the elderly that suffer from incontinence. | Location Research Triangle Park |
| |
Company Doron Therapeutics | Activity: Research and Development | Company Description Doron Therapeutics is developing an injectable biologic to treat osteoarthritis and other musculoskeletal diseases. | Location Chapel Hill |
| |
Company DotBio LLC | Activity: Research and Development | Company Description DotBio develops immuno-oncology therapies. | Location Weddington |
| |
Company Drive Therapeutics LLC | Activity: Research and Development | Company Description Drive Therapeutics is developing therapeutics for wet age-related macular degeneration (wAMD) and diabetic retinopathy/diabetic macular edema (DR/DME). | Location Research Triangle Park |
| |
Company Dualogics LLC | Activity: Research and Development | Company Description Dualogics researches and develops bispecific antibody products based on their proprietary OrthoMab platform. | Location Durham |
| |
Company DuraVax Inc. | Activity: Research and Development | Company Description DuraVax is developing thermo-stable liquid formulations for RNA pharmaceuticals. | Location Wilmington |
| |
Company Eclipse Life Sciences Inc. | Activity: Research and Development | Company Description Eclipse Life Sciences is developing therapeutic compounds to treat front-of-the-eye diseases, such as uveitis and dry eye, as well as back-of-the-eye diseases, such as wet or dry macular degeneration or diabetic retinopathy. | Location Research Triangle Park |
| |
Company Eisai Inc. | Activity: Sales and Operations | Company Description Eisai discovers, develops and markets pharmaceuticals in neurology and oncology-critical care. This site supports global partnerships, quality assurance and supply chain for the company. | Location Raleigh |
| |
Company Eldec Pharmaceuticals Inc. | Activity: Research and Development | Company Description Eldec Pharmaceuticals is developing anti-inflammatory peptides for the treatment of chronic lung disease. | Location Durham |
| |
Company Emergo Therapeutics Inc. | Activity: Research and Development | Company Description Emergo Therapeutics develops drugs to reduce the production of inflammatory cytokines from mast cells and improve the functioning of the immune system in various potential indications, starting with infectious diseases. | Location Durham |
| |
Company Endacea Inc. | Activity: Research and Development | Company Description Endacea develops A1 adenosine receptor antagonists as drug candidates for cancer, COVID-19 acute lung injury, sepsis and acute renal failure. | Location Research Triangle Park |
| |
Company ENVIGEN Pharmaceuticals Inc. | Activity: Research and Development | Company Description ENVIGEN develops classes of small drug-like molecules to treat life-threatening diseases including cancer, HIV/AIDS and neurological disorders. | Location Durham |
| |
Company Enzerna Biosciences Inc. | Activity: Research and Development | Company Description Enzerna Biosciences is a pre-clinical stage company that is leveraging its proprietary RNA editing technology to develop long-term curative gene therapies for rare genetic disorders such as Huntington's Disease and Myotonic Dystrophy. | Location Morrisville |
| |
Company Epigenos Biosciences Inc. | Activity: Research and Development | Company Description Epigenos Biosciences develops personalized epigenome-based therapeutics that leverage site-specific DNA binding technologies to treat disease at the root of gene mis-regulation. | Location Morrisville |
| |
Company Eppin Pharma Inc. | Activity: Research and Development | Company Description Eppin Pharma is developing a non-hormonal male oral contraceptive. | Location Durham |
| |
Company ER Therapeutics LLC | Activity: Research and Development | Company Description ER Therapeutics is developing and commercializing therapeutics for cancer. | Location Chapel Hill |
| |
Company Evecxia Inc. | Activity: Research and Development | Company Description Evecxia is developing drugs which amplify serotonin synthesis to treat neuropsychiatric conditions for which current therapies are inadequate. | Location Research Triangle Park |
| |
Company EydisBio Inc. | Activity: Research and Development | Company Description Eydis Bio is developing a platform of small molecule therapeutics targeting a variety of diseases driven by aberrant inflammatory/autoimmune processes. | Location Durham |
| |
Company Eyedesis Biosciences LLC | Activity: Research and Development | Company Description Eyedesis Biosciences is developing a small-molecule macrophage inhibitor for the treatment of neovascular age related macular degeneration. | Location Chapel Hill |
| |
Company FastBack Bio LLC | Activity: Research and Development | Company Description FastBack Bio is developing CAR-T therapy for treatment of solid tumors. | Location Raleigh |
| |
Company Fennec Pharmaceuticals Inc. | Activity: Research and Development | Company Description Fennec Pharmaceuticals develops a sodium thiosulfate formula for the prevention of ototoxicity from cisplatin in pediatric patients. | Location Research Triangle Park |
| |
Company Fernel Therapeutics Inc. | Activity: Research and Development | Company Description Fernel Therapeutics develops medical devices and pharmaceuticals for the treatment of benign or non-infectious diseases of the pelvic region. | Location Apex |
| |
Company Fervent Pharmaceuticals LLC | Activity: Research and Development | Company Description Fervent Pharmaceuticals develops a nonhormonal product, FP-101, to treat vasomotor symptoms associated with menopause. | Location Greenville |
| |
Company FLAG Therapeutics Inc. | Activity: Research and Development | Company Description FLAG Therapeutics develops cancer therapeutics using new classes of small molecules which have selective dual activity: antiangiogenesis and chemotherapeutic. | Location Raleigh |
| |
Company G1 Therapeutics Inc. | Activity: Research and Development | Company Description G1 Therapeutics is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for those affected by cancer. | Location Research Triangle Park |
| |
Company Gateway Bio Inc. | Activity: Research and Development | Company Description Gateway Bio is developing a rapid onset anticoagulant. | Location Durham |
| |
Company Genebiology Inc. | Activity: Research and Development | Company Description GeneBiology identifies, patents and develops new parenteral formulations of approved drugs for unmet medical needs using the 505b2 regulatory pathway. | Location Research Triangle Park |
| |
Company Genencine Therapeutics LLC | Activity: Research and Development | Company Description Genencine Therapeutics develops mRNA vaccines for the prevention and treatment of cancer, viral diseases and autoimmune diseases, as well as mRNA therapeutic drugs for genetic diseases. | Location Durham |
| |
Company Generys Biopharmaceuticals Corp. | Activity: Research and Development | Company Description Generys BioPharmaceuticals develops drugs, formulations and generics for unmet medical needs. Generys also offers therapeutic pipeline portfolio consulting and management services on a contract basis. | Location Chapel Hill |